相似文献
1
Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021.2016年至2021年美国食品药品监督管理局不良事件报告系统中报告的银屑病不良事件及相关药物。
JAAD Int. 2022 Apr 18;7:144-145. doi: 10.1016/j.jdin.2022.03.010. eCollection 2022 Jun.
2
Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration's Adverse Event Reporting System, 2010-2017.2010-2017 年，美国食品和药物管理局不良事件报告系统报告的与使用 sipuleucel-T 相关的不良事件。
JAMA Netw Open. 2019 Aug 2;2(8):e199249. doi: 10.1001/jamanetworkopen.2019.9249.
3
The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.韦伯效应与美国食品药品监督管理局不良事件报告系统（FAERS）：对2006年至2010年批准的62种药物的分析
Drug Saf. 2014 Apr;37(4):283-94. doi: 10.1007/s40264-014-0150-2.
4
Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).美国食品和药物管理局不良事件报告系统（FAERS）中的颌骨骨坏死。
J Bone Miner Res. 2016 Feb;31(2):336-40. doi: 10.1002/jbmr.2693. Epub 2015 Sep 4.
5
Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System.静脉镇静剂相关严重心血管不良事件报告：MedWatch不良事件报告系统的回顾性分析
Drugs Real World Outcomes. 2019 Sep;6(3):141-149. doi: 10.1007/s40801-019-00161-y.
6
Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.炎症性疾病中肿瘤坏死因子 α 拮抗剂相关的银屑病：FDA 不良事件报告系统分析。
Inflamm Bowel Dis. 2013 May;19(6):1164-72. doi: 10.1097/MIB.0b013e31828075bd.
7
Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration's Adverse Event Reporting System Narratives.自动识别食品和药物管理局不良事件报告系统叙述中的药物和不良事件信息。
JMIR Med Inform. 2014 Jun 27;2(1):e10. doi: 10.2196/medinform.3022.
8
Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.1969 - 2002年美国药品不良事件监测与药物撤市：报告疑似不良反应的重要性
Arch Intern Med. 2005 Jun 27;165(12):1363-9. doi: 10.1001/archinte.165.12.1363.
9
10
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.阿扎那韦相关肾结石：来自美国食品药品监督管理局不良事件报告系统的病例
AIDS. 2007 May 31;21(9):1215-8. doi: 10.1097/QAD.0b013e32813aee35.
引用本文的文献
1
Demographics, Clinical Characteristics, and Treatment Patterns in Patients with Psoriasis: Insights from the Saudi Arabia Psoriasis Registry (PSORSA).银屑病患者的人口统计学、临床特征及治疗模式：来自沙特阿拉伯银屑病登记处（PSORSA）的见解
Dermatol Ther (Heidelb). 2025 May 14. doi: 10.1007/s13555-025-01436-9.
本文引用的文献
1
Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy.生物制剂（抗 TNF-α 治疗以外）所致不良反应中的银屑病。
Eur J Dermatol. 2021 Jun 1;31(3):307-317. doi: 10.1684/ejd.2021.4056.
2
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.托珠单抗治疗重症 COVID-19 肺炎住院患者。
N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25.
3
Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis.氯喹和羟氯喹治疗 COVID-19 的系统评价和荟萃分析。
J Gen Intern Med. 2020 Nov;35(11):3308-3314. doi: 10.1007/s11606-020-06146-w. Epub 2020 Sep 3.
4
Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level.β受体阻滞剂诱发银屑病及新发银屑病在细胞水平的机制
Cureus. 2020 Jul 2;12(7):e8964. doi: 10.7759/cureus.8964.
5
Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance.药物诱发的银屑病：是药物诱导还是药物加重？：了解病理生理学和临床相关性。
J Clin Aesthet Dermatol. 2010 Jan;3(1):32-8.
Zotero 插件